An overview of biosimilars for cancer, diabetes mellitus, rheumatoid arthritis and other immune-mediated diseases approved between 2016 and 2021
The steep rise in the cost of brand name biologics and expiration of their patents led to the arrival of several new biosimilars in the United States (US) and European Union (EU) markets. Indian pharma companies have also taken initiatives for bringing lower cost similar biologics to the market and...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Results in Chemistry |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211715622000753 |